The manufacturer of Nulibry, a recently approved, first-of-its-kind injectable treatment for a very rare, often fatal genetic disorder that typically appears soon after birth, has posted details about the limited distribution network for the drug on the U.S. Health Resources and Services Administration’s (HRSA) 340B program website.
The manufacturer, Origin Biosciences, said it is limiting distribution to hospital inpatient facilities and just one specialty pharmacy, Biologics by McKesson. It said it doing so because it makes Nulibry in small quantities, the drug requires “stringent conditions” for cold storage, and dispensing pharmacists need special training.
The manufacturer of Nulibry, a recently approved, first-of-its-kind injectable treatment for a very rare, often fatal genetic disorder that typically appears soon after birth, has posted details about the limited distribution network for the drug on the U.S. Health Resources and Services Administration’s (HRSA) 340B program website.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
